Scancell eyes key cancer milestones and data

Scancell Holdings (AIM:SCLP) is entering a pivotal period with key clinical data readouts anticipated in late 2025 for its lead cancer programs, iSCIB1+ for melanoma and Modi-1 for head/neck and kidney cancers, following promising Phase II results and preparation for larger randomized trials in 2026. The biotech firm has also expanded its pipeline with a GlyMab antibody platform, securing a licensing deal with Genmab valued at up to $630 million in milestone payments. Financially, Scancell reported a narrowed operating loss of £15 million and extended its cash runway into H2 2026, signaling strong clinical and organizational progress towards near-term developmental milestones.

Analysis

Scancell Holdings is positioned at a critical inflection point, with significant clinical and financial momentum heading into late 2025 and 2026. The company's lead asset, iSCIB1+, has demonstrated marked improvements in progression-free survival in Phase II melanoma trials, with further data from the SCOPE trial expected later this year, setting the stage for pivotal randomised trials in 2026. This is complemented by its Modi-1 vaccine, which showed a strong 43% response rate in head and neck cancer patients when combined with a checkpoint inhibitor—a figure noted as well above typical results—with additional data in kidney cancer due in Q4. The strategic value of its pipeline is further validated by a licensing deal for its GlyMab antibody platform with Genmab, securing $6 million upfront and up to $630 million in potential milestones. Financially, the company has strengthened its position by narrowing its operating loss to £15 million from £18.3 million and, more importantly, extending its cash runway into the second half of 2026 with a cash balance of £16.9 million, mitigating near-term financing risks and fully funding operations through its upcoming key data readouts.

Key Decisions for Investors

• Investors should focus on the second half of 2025 as a period of significant catalysts, with data readouts from both the iSCIB1+ (melanoma) and Modi-1 (head/neck, kidney cancer) trials expected to be primary drivers of valuation.
• The extended cash runway into H2 2026 is a key de-risking event, as it suggests the company is fully funded to reach these pivotal clinical milestones, reducing the immediate threat of dilutive financing.
• While the interim data is highly encouraging, the investment thesis is contingent on the full results confirming efficacy; therefore, a position should be stress-tested against the risk of trial outcomes not meeting the high expectations set by early readouts.